Noninvasive Type 2 Diabetes Screening: Clinical Evaluation of SCOUT DS in an Asian Indian Cohort
2012; Mary Ann Liebert, Inc.; Volume: 15; Issue: 1 Linguagem: Inglês
10.1089/dia.2012.0204
ISSN1557-8593
AutoresViswanathan Mohan, C.S. Shanthi Rani, Bhaskaran S. Regin, Muthuswamy Balasubramanyam, Ranjit Mohan Anjana, Nathaniel I. Matter, Subramani Poongothai, Mohan Deepa, Rajendra Pradeepa,
Tópico(s)Skin Diseases and Diabetes
ResumoThis study evaluated the noninvasive, point-of-care diabetes screening device, Scout DS (VeraLight Inc., Albuquerque, NM) (SCOUT), in a native Asian Indian cohort.SCOUT is a tabletop, skin fluorescence spectrometer that reports a risk score following a 3-4-min noninvasive measurement of a subject's left volar forearm. SCOUT, fasting plasma glucose (FPG), and hemoglobin A(1c) (A1C) were compared for detection of abnormal glucose tolerance (AGT) in a cohort of 256 subjects without previous diagnosis of diabetes or impaired glucose tolerance in Chennai, India. After an overnight fast, a 75-g, 2-h oral glucose tolerance test was administered, and AGT was defined as a plasma glucose value ≥ 140 mg/dL (7.8 mmol/dL). Sensitivity, false-positive rate (FPR), and receiver-operating characteristics area under the curve for AGT detection were computed for SCOUT, FPG, and A1C. Intra-day reproducibility of SCOUT was assessed.SCOUT, FPG, and A1C (at respective thresholds of 50, 110 mg/dL, and 5.7%) exhibited sensitivities of 87%, 32%, and 86%, respectively, and FPR of 52%, 3%, and 58%, respectively. For the 177 subjects receiving a valid SCOUT Diabetes Score on both measurement attempts, the coefficient of variation was 5.8%, and the Pearson correlation was 0.91. A SCOUT score could be obtained on 91% of subjects after two attempts.The performance of SCOUT is similar to that of A1C, whereas FPG had a much lower sensitivity. SCOUT is an effective tool for AGT screening in Asian Indians.
Referência(s)